Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
"These studies actually show that both treatments are effective," said Paul Lynch, MD, co-founder of Arizona Pain Specialists. "The studies did
not use a true control group condition, where patients would receive no treatment. The 'control' patients actually received a different effective tre...
AutoImmune Inc. Reports 2009 Second Quarter Financial Results
... BioMS Medical Corp. and Eli Lilly and Company recently reported that dirucotide, the lead drug covered by AutoImmune's license agreement with BioMS, did
not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year Phase I...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...cted FVC at Week 72 and secondary endpoints of progression-free survival and categorical change in percent predicted FVC.
While CAPACITY 1 did
not achieve statistical significance on the primary endpoint at Week 72, the results were generally consistent with and supportive of CAPACITY 2.
OncoGenex Reports Second Quarter 2009 Financial Results
...arter and six months ended June 30, 2008 also included $0.8 million and $1.6 million respectively in preferred share accretion, a non-cash item, which did
not recur in the second quarter or six months ended June 30, 2009, as subsequent to the reverse takeover there are no preferred shares outstanding.
The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict
...e Defendant, an osteopathic physician and registered pharmacist, prescribed it to her for gout. Plaintiff disputed the diagnosis and alleged that she did
not have gout. The doctor claimed that she told him she had gout and described pain in her toe consistent with gout. He prescribed Allopurinol in or...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
...ng the impact of foreign currency changes, revenue would have declined by 10% as compared to the second quarter of 2008. Foreign currency fluctuations did
not have an impact on the change from the first quarter of 2009.
The decline in our Base Medical Products sales as compared to the second quarter of...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... the FDA
for INTUNIV. Shire and the FDA were not able to reach agreement on
final product labeling in time to meet the PDUFA date. The FDA did
identify safety concerns regarding INTUNIV, request new clinical data or
additional analyses in the Complete Response Letter. Shire an...
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
...ant treatment effect on the primary endpoint emerged, while several additional secondary endpoints also showed improvement. In contrast, on no measure did
sham patients perform better than CERE-120 patients, at either 12 or 18 months. Based on those findings, and insight gained from analyses of post-mort...
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
...cell transplant centers in the United States and France. Although orBec(R) did
not achieve statistical significance in the primary endpoint of its pivotal... median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did
achieve statistical significance in other key secondary endpoints such as t...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
...gnificantly improved symptoms of major depressive disorder for patients who did
not respond to an older drug, Forest Laboratories Inc.'s Celexa. TC-5214 wa...t the FDA plans to re-inspect a key manufacturing plant because the company did
not take sufficient action to correct equipment maintenance and process con...
Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
...tanza NDA. The AIDAC voted that Restanza demonstrated safety for the outpatient treatment of adults with mild-to-moderate CAP, but voted that Restanza did
not demonstrate efficacy in the treatment of CAP. The committee's negative vote on the drug candidate's efficacy followed a discussion that the Restan...
PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
...ly 24, 2009. The Warrants will be exercisable for a period of five years beginning six months after the closing of the private placement. The Company did
not engage a placement agent in connection with this transaction.
About the Securities
The securities that are being sold in the transactio...
Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA)
... illnesses. Rosalind advises how work or career can be possible despite a diagnosis of RA.
Ellen Shmueli , diagnosed with RA at the age of 28, did
not let the disease stop her from becoming a certified fitness instructor. Ellen shares her personal story and demonstrates several RA-friendly exerci...
Sanofi-aventis Announces Second Quarter 2009 Results
...y evaluating xaliproden in the prevention of severe peripheral sensory neuropathy induced by oxaliplatin in patients with metastatic colorectal cancer did
not attain its primary end point. It was therefore decided to discontinue development of this product. It has also been decided not to proceed with th...
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
... serious, dose-limiting or definitively drug-related adverse events reported. All clinical adverse events observed were mild or moderate in severity, did
not require intervention, and were not clearly related to PTC299. In addition, adverse events such as bleeding, hypertension and proteinuria were not...
Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
...atistically significant (p<0.05) increase in the number of terminal hairs, cumulative hair thickness density and hair thickness mean. Perturbation did
not enhance the results seen with HSC. There were no adverse reactions seen in any of the treated 24 patients at baseline, 12 weeks, or the 22 week en...
TorreyPines Receives Notice of Delisting from Nasdaq Global Market
... TPTX ) announced today that it had received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that it did
not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5450(b)(1)(A), prior to the e...
Material world: Graphene's versatility promises new applications
...ance, were subjected to detailed measurement. The results show that graphene's capacitance is very small. Further, the quantum capacitance of graphene did
not precisely duplicate theoretical predictions for the behavior of ideal graphene. This is due to the fact that charged impurities occur in experimen...
REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
...ung adult must balance this risk with the clinical need. Short-term studies did
not show an increase in the risk of suicidality with antidepressants compar...pressive disorder (MDD) and other psychiatric disorders. Short-term studies did
not show an increase in the risk of suicidality with antidepressants compar...
Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
...ly to look after them.
Autologous cell therapy has been studied as an innovative treatment option for CLI, however; previously published studies did
not use a rapid, point of care method for processing the cells therefore making widespread adoption of the therapy problematic. The Harvest trial util...
Stem cells' 'suspended' state preserved by key step, scientists report
...hich small RNAs bind to other RNAs to increase or decrease their activity.) In this case, the scientists used the technique to silence Chd1. When they did
so, embryonic stem cells could not make the full range of specialized cells.
In a laboratory test used to simulate normal cell specialization, the...
CEL-SCI Corporation Releases Letter to Shareholders
...cold aseptic fill will be offered to the industry as a contract service. I leave you with one simple thought: how would your life be affected if you did
not have a refrigerator or freezer? We believe that the 4 degree Centigrade cold aseptic fill has the same kind of impact on the pharmaceutical/biote...
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
...ered and paid in the initial offering period.
The subsequent offering period enables holders of shares of Cougar Biotechnology common stock who did
not tender during the initial offering period to participate in the offer and receive the offer price on an expedited basis rather than waiting until ...
Unexpectedly long-range effects in advanced magnetic devices
... found surprised them.
As expected, the ferromagnetic material directly under the grid lines showed the pinning effect, but, quite unexpectedly, so did
the uncovered material in regions between the grid lines far removed from the antiferromagnetic material. "This pinning effect extends for maybe tens ...
First step to converting solar energy using 'artificial leaf'
...and his colleagues successfully determined the detailed molecular and supramolecular structure of their artificial self-assembled light antennae. They did
this using a combination of solid state NMR and X-ray diffraction (see attachment). X-ray diffraction enabled them to determine the overall structure ...
FDA Inspects Hovione's API Manufacturing Plant in Macau
...l Manager of the plant, said "The inspection
was focused on the execution side rather than the documentation system.
Inspectors wanted to know "how we did
in specific situations" rather than
"how we should do in hypothetical situations" . I am glad that we continue to
do well in compliance issues."
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
... The results of the trial indicated that IPLEX(TM) did
not exhibit a statistically significant improvemen...n, commented, "We are disappointed that this trial did
not meet the majority of its functional endpoints....d, "While the phase II clinical trial of IPLEX(TM) did
not show efficacy in the overall MMD population in...
First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.
...e goal was to build a program to give intended parents more control over their egg donor search process, as well as create a positive unification that did
not previously exist within the industry. "We are delighted to bring together some of the most credible and esteemed agencies across the country, whil...
Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
...e response induced by the VLP vaccine," said Ted Ross, Ph.D., Assistant Professor, Center for Vaccine Research, University of Pittsburgh . "Not only did
the vaccine induce robust HAI responses, it also induced HA-specific CD8+ T cell responses that were superior to those of a split vaccine. This findi...
CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
...ood and spleen cells from immunized mice produced gamma interferon in response to the vaccine, while the cells from mice in the various control groups did
not. Other recent L.E.A.P.S. data, presented by Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio...
The MedZilla Report: May 2009 Employment Outlook for Biotech/Pharma/Health
... to the Associated Press, faced a 69 percent drop in profits after fourth quarter 2008. Minnesota-based health systems continued feeling the pinch, as did
several facilities across New England. New Jersey's Horizon Blue Cross Blue Shield said a combination of factors including employers cutting the benef...
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
...was no evidence of Grade III or IV rash at any of the three dose levels nor did
nimotuzumab increase the toxicity of radiotherapy. Based on these results, ...all survival (p = 0.0018) favoring nimotuzumab. The addition of nimotuzumab did
not add to the toxicities of either regimen, with no Grade III/IV skin toxi...
Neogen Named to Fortune's List of 40 Stocks 'To Retire On'
...in 2002, stating: "We wanted to assemble a diversified, dependable portfolio of stocks for the long term - a selection that could soar when the market did
but also hold steady during darker times."
"We are pleased any time we receive independent recognition of Neogen's outstanding performance, and ...
Israeli scientists show bacteria can plan ahead
...opped giving the dogs food after ringing the bell, the conditioned response faded until they eventually ceased salivating at its sound. The scientists did
something similar, using bacteria grown by Dr. Erez Dekel, in the lab of Prof. Uri Alon of the Molecular Cell Biology Department, in an environment co...
Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures
...es of 9 and 15 mcg/day administered with daily weight-based RBV. The study tested 2 dosages of INFERGEN in 487 documented non-responders, of which 80% did
not achieve a 2-log drop on prior pegylated-interferon plus ribavirin therapy. The best SVR rates were seen in:
DNA Diagnostics Center Offers Father's Day DNA Testing
... more fathers are learning the truth every day.
DNA Diagnostics Center also offers Y-chromosome testing that can answer the question, "Where did
my dad's ancestors begin?" DNA can trace male lineage back tens of thousands of years, and any man can find out where his paternal ancestors star...
New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
...tly developed genotypic tropism tests was comparable to the concordance of each assay with the Trofile, and that the proportion of X4 viruses detected did
not vary significantly by assay type.
Quest Diagnostics had offered a prior version of the SensiTrop test through a license with Pathway Diagnos...
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
...es and after the booster dose showed that a high percentage of infants receiving Prevenar 13 had functional antibodies for all serotypes. Prevenar 13 did
not affect responses to the concomitantly administered vaccine and showed a safety profile comparable to Prevenar.
A study of 352 children in ...
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
...o., June 9 /PRNewswire/ -- Teva Neuroscience, Inc. today presented results from a clinical pharmacology study in which AZILECT(R) (rasagiline tablets) did
not increase the risk of tyramine sensitivity at the maximum approved dose of 1 mg. The presentation was made during the 13th International Congress o...
Matrix Genomics, Elizabeth Corder, PhD - Gene Variation in the LRRK2 Gene and High Risk for Parkinson's Disease
...netic test for Parkinson's disease (Patent pending).
Earlier work had identified each of the four variants as being associated with PD risk, but did
not combine the information to make a specific risk signature.
Genetic testing using this approach is expected to identify a third of persons at v...